The WACC of Genfit SA (GNFT.PA) is 7.1%.
Range | Selected | |
Cost of equity | 6.0% - 9.9% | 7.95% |
Tax rate | 1.0% - 2.1% | 1.55% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 5.7% - 8.5% | 7.1% |
Category | Low | High |
Long-term bond rate | 3.0% | 3.5% |
Equity market risk premium | 5.8% | 6.8% |
Adjusted beta | 0.51 | 0.86 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 6.0% | 9.9% |
Tax rate | 1.0% | 2.1% |
Debt/Equity ratio | 0.37 | 0.37 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 5.7% | 8.5% |
Selected WACC | 7.1% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
GNFT.PA | Genfit SA | 0.37 | 1.62 | 1.19 |
ADL.MC | ADL Bionatur Solutions SA | 0.49 | 0.33 | 0.22 |
ALONC.PA | Oncodesign SA | 0.26 | 1.16 | 0.92 |
BINV.ST | BioInvent International AB | 0.01 | 0.53 | 0.53 |
DMYD B.ST | Diamyd Medical AB | 0.02 | 0.17 | 0.16 |
IPH.PA | Innate Pharma SA | 0.5 | 0.99 | 0.66 |
OSE.PA | Ose Immunotherapeutics SA | 0.35 | 1.19 | 0.88 |
POXEL.PA | Poxel SA | 2.12 | -0.24 | -0.08 |
SANION.ST | Saniona AB | 0.01 | -0.76 | -0.76 |
TILS.L | Tiziana Life Sciences PLC | 0.01 | -1.34 | -1.34 |
Low | High | |
Unlevered beta | 0.2 | 0.58 |
Relevered beta | 0.27 | 0.79 |
Adjusted relevered beta | 0.51 | 0.86 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for GNFT.PA:
cost_of_equity (7.95%) = risk_free_rate (3.25%) + equity_risk_premium (6.30%) * adjusted_beta (0.51) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.